Genetic testing for familial hypercholesterolemia: Impact on diagnosis,treatment and cardiovascular risk

Abstract

Aims

Familial hypercholesterolemia (FH) is the most common genetic disorder in medicine, with a prevalence of 1/250. Affected individuals have elevated low-density lipoprotein cholesterol (LDL-C) and an increased lifetime risk of atherosclerotic cardiovascular disease (ASCVD). The diagnosis of FH is based on algorithms that include LDL-C levels, physical manifestations, family history of high LDL-C and premature ASCVD, and, more recently, genetic testing. We sought to determine the impact of genetic testing on the: 1) diagnosis of ‘definite familial hypercholesterolemia’, 2) initiation and adherence of lipid-lowering therapy and 3) risk of ASCVD.

Methods

We performed a systematic review and meta-analysis, pooling odds ratios and 95% confidence intervals for ASCVD from studies comparing risk estimates in individuals harboring FH-causing variants and unaffected individuals.

Results

After screening 3304 unique publications, 56 studies were included in the analysis. 1) Genetic testing provided confirmation of FH in 28–80%, over clinical criteria alone, depending on the diagnostic algorithm and the method of analysis. In two large population-based studies comprising 76,751 individuals, an FH-causing variant was identified in only 1.7–2.5% of subjects with an LDL-C > 4.9 mmol/L (190 mg/dL). 2) A confirmed molecular diagnosis increased lipid-lowering therapy adherence (five studies, n = 4181 definite FH). 3) Loss-of-function variant of the LDLR were at a markedly increased risk of myocardial infarction (odds ratio 6.77, 95% confidence interval 4.75–9.66), and patients with a milder (hypomorphic) pathogenic LDLR change had a 4.4-fold increase in risk (odds ratio 4.4, 95% confidence interval 2.34–8.26), compared with controls.

Conclusion

DNA sequencing confirms the diagnosis of FH but has a poor yield in unselected patients whose sole criterion is an elevated LDL-C. Initiation and adherence to treatment is improved. The risk of ASCVD is 4.4- to 6.8-fold increased in patients with an FH-causing variant compared with controls, depending on the severity of the DNA change.

Keywords

Familial hypercholesterolemia low-density lipoprotein genetic testing atherosclerotic cardiovascular disease

Get full access to this article

View all access options for this article.

References

Nordestgaard

Chapman

Humphries

et al.

Familial hypercholesterolaemia is underdiagnosed and undertreated in the general population: Guidance for clinicians to prevent coronary heart disease: Consensus statement of the European Atherosclerosis Society. Eur Heart J 2013; 34: 3478–3490a.

Genest

Hegele

Bergeron

et al.

Canadian Cardiovascular Society position statement on familial hypercholesterolemia. Can J Cardiol 2014; 30: 1471–1481.

Ruel

Brisson

Aljenedil

et al.

Simplified Canadian definition for familial hypercholesterolemia. Can J Cardiol 2018; 34: 1210–1214.

Reiner

. Management of patients with familial hypercholesterolaemia. Nat Rev Cardiol 2015; 12: 565–575.

Akioyamen

Genest

Shan

et al.

Estimating the prevalence of heterozygous familial hypercholesterolaemia: A systematic review and meta-analysis. BMJ Open 2017; 7: e016461.

Cuchel

Bruckert

Ginsberg

et al.

Homozygous familial hypercholesterolaemia: New insights and guidance for clinicians to improve detection and clinical management. A position paper from the Consensus Panel on Familial Hypercholesterolaemia of the European Atherosclerosis Society. Eur Heart J 2014; 35: 2146–2157.

Graham

Latten

Hart

. Molecular diagnosis of familial hypercholesterolaemia. Curr Opin Lipidol 2017; 28: 313–320.

Futema

Shah

Cooper

et al.

Refinement of variant selection for the LDL cholesterol genetic risk score in the diagnosis of the polygenic form of clinical familial hypercholesterolemia and replication in samples from 6 countries. Clin Chem 2015; 61: 231–238.

National Institutes for Clinical Excellence (NICE). Familial hypercholesterolaemia: identification and management. National Institutes for Clinical Excellence (NICE) Clinical Guideline CG71. Available at: https://www.nice.org.uk/guidance/cg71 (published August 2008, updated November 2017, accessed 8 May 2018).

10.

Versmissen

Oosterveer

Yazdanpanah

et al.

Efficacy of statins in familial hypercholesterolaemia: A long term cohort study. BMJ 2008; 337: a2423.

11.

Goldstein

Brown

. A century of cholesterol and coronaries: From plaques to genes to statins. Cell 2015; 161: 161–172.

12.

Stroup

Berlin

Morton

et al.

Meta-analysis of observational studies in epidemiology: A proposal for reporting. Meta-analysis Of Observational Studies in Epidemiology (MOOSE) group. JAMA 2000; 283: 2008–2012.

13.

DerSimonian

Laird

. Meta-analysis in clinical trials. Control Clin Trials 1986; 7: 177–188.

14.

Jannes

Santos

de Souza Silva

et al.

Familial hypercholesterolemia in Brazil: Cascade screening program, clinical and genetic aspects. Atherosclerosis 2015; 238: 101–107.

15.

Khera

Won

Peloso

et al.

Diagnostic yield and clinical utility of sequencing familial hypercholesterolemia genes in patients with severe hypercholesterolemia. J Am Coll Cardiol 2016; 67: 2578–2589.

16.

Perez de Isla

Alonso

Mata

et al.

Coronary heart disease, peripheral arterial disease, and stroke in familial hypercholesterolaemia: Insights from the SAFEHEART Registry (Spanish Familial Hypercholesterolaemia Cohort Study). Arterioscler Thromb Vasc Biol 2016; 36: 2004–2010.

17.

Abul-Husn

Manickam

Jones

et al.

Genetic identification of familial hypercholesterolemia within a single U.S. health care system. Science 2016, pp. 354.

18.

Moorjani

Roy

Gagne

et al.

Homozygous familial hypercholesterolemia among French Canadians in Quebec Province. Arteriosclerosis 1989; 9: 211–216.

19.

Umans-Eckenhausen

Defesche

Sijbrands

et al.

Review of first 5 years of screening for familial hypercholesterolaemia in the Netherlands. Lancet 2001; 357: 165–168.

20.

Umans-Eckenhausen

Defesche

van Dam

et al.

Long-term compliance with lipid-lowering medication after genetic screening for familial hypercholesterolemia. Arch Intern Med 2003; 163: 65–68.

21.

Leren

Manshaus

Skovholt

et al.

Application of molecular genetics for diagnosing familial hypercholesterolemia in Norway: Results from a family-based screening program. Semin Vasc Med 2004; 4: 75–85.

22.

Huijgen

Kindt

Verhoeven

et al.

Two years after molecular diagnosis of familial hypercholesterolemia: Majority on cholesterol-lowering treatment but a minority reaches treatment goal. PLoS One 2010; 5: e9220.

23.

Avis

Kusters

Vissers

et al.

Follow-up of children diagnosed with familial hypercholesterolemia in a national genetic screening program. J Pediatr 2012; 161: 99–103.

24.

Gaudet

Vohl

Couture

et al.

Contribution of receptor negative versus receptor defective mutations in the LDL-receptor gene to angiographically assessed coronary artery disease among young (25–49 years) versus middle-aged (50–64 years) men. Atherosclerosis 1999; 143: 153–161.

25.

Umans-Eckenhausen

Sijbrands

Kastelein

et al.

Low-density lipoprotein receptor gene mutations and cardiovascular risk in a large genetic cascade screening population. Circulation 2002; 106: 3031–3036.

26.

Sturm

Knowles

Gidding

et al.

Clinical genetic testing for familial hypercholesterolemia: JACC Scientific Expert Panel. J Am Coll Cardiol 2018; 72: 662–680.

27.

Modell

Greendale

Citrin

et al.

Expert and advocacy group consensus findings on the horizon of public health genetic testing. Healthcare (Basel) 2016; 4: 1–20.

28.

Nordestgaard

Benn

. Genetic testing for familial hypercholesterolaemia is essential in individuals with high LDL cholesterol: Who does it in the world?. Eur Heart J 2017; 38: 1580–1583.

29.

Besseling

Reitsma

Gaudet

et al.

Selection of individuals for genetic testing for familial hypercholesterolaemia: Development and external validation of a prediction model for the presence of a mutation causing familial hypercholesterolaemia. Eur Heart J 2017; 38: 565–573.

30.

Mundal

Igland

Ose

et al.

Cardiovascular disease mortality in patients with genetically verified familial hypercholesterolemia in Norway during 1992–2013. Eur J Prev Cardiol 2017; 24: 137–144.

31.

Kerr

Pears

Miedzybrodzka

et al.

Cost effectiveness of cascade testing for familial hypercholesterolaemia, based on data from familial hypercholesterolaemia services in the UK. Eur Heart J 2017; 38: 1832–1839.

32.

Knowles

O'Brien

Greendale

et al.

Reducing the burden of disease and death from familial hypercholesterolemia: A call to action. Am Heart J 2014; 168: 807–811.

33.

Louter

Defesche

Roeters van Lennep

. Cascade screening for familial hypercholesterolemia: Practical consequences. Atheroscler Suppl 2017; 30: 77–85.

34.

Brunham

Ruel

Aljenedil

et al.

Canadian Cardiovascular Society position statement on familial hypercholesterolemia: Update 2018. Can J Cardiol 2018; 34: 1553–1563.

35.

Johansen

Dube

Loyzer

et al.

LipidSeq: A next-generation clinical resequencing panel for monogenic dyslipidemias. J Lipid Res 2014; 55: 765–772.

36.

Hagger

Hardcastle

et al.

Health literacy in familial hypercholesterolemia: A cross-national study. Eur J Prev Cardiol 2018; 25: 936–943.

37.

EAS Familial Hypercholesterolaemia Studies Collaboration; EAS Familial Hypercholesterolaemia Studies Collaboration (FHSC) Investigators. Overview of the current status of familial hypercholesterolaemia care in over 60 countries – The EAS Familial Hypercholesterolaemia Studies Collaboration (FHSC). Atherosclerosis 2018; 277: 234–55.

Supplementary Material

Please find the following supplemental material available below.

For Open Access articles published under a Creative Commons License, all supplemental material carries the same license as the article it is associated with.

For non-Open Access articles published, all supplemental material carries a non-exclusive license, and permission requests for re-use of supplemental material or any part of supplemental material shall be sent directly to the copyright owner as specified in the copyright notice associated with the article.

0.00 MB

1.31 MB